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refractory atrial ﬁbrillation (AF). Although results are suboptimal, it is unknown whether mechanistically-based strategies
targeting AF drivers are superior.
OBJECTIVES This study sought to determine the efﬁcacy and safety of localized high-frequency source ablation (HFSA)
compared with CPVI in patients with drug-refractory AF.
METHODS This prospective, multicenter, single-blinded study of 232 patients (age 53  10 years, 186 males) ran-
domized those with paroxysmal AF (n ¼ 115) to CPVI or HFSA-only (noninferiority design) and those with persistent AF
(n ¼ 117) to CPVI or a combined ablation approach (CPVI þ HFSA, superiority design). The primary endpoint was freedom
from AF at 6 months post-ﬁrst ablation procedure. Secondary endpoints included freedom from atrial tachyarrhythmias
(AT) at 6 and 12 months, periprocedural complications, overall adverse events, and quality of life.
RESULTS In paroxysmal AF, HFSA failed to achieve noninferiority at 6 months after a single procedure but, after redo
procedures, was noninferior to CPVI at 12months for freedom fromAF and AF/AT. Serious adverse events were signiﬁcantly
reduced in the HFSA group versus CPVI patients (p¼ 0.02). In persistent AF, there were no signiﬁcant differences between
treatment groups for primary and secondary endpoints, but CPVI þ HFSA trended toward more serious adverse events.
CONCLUSIONS In paroxysmal AF, HFSA failed to achieve noninferiority at 6 months but was noninferior to CPVI at
1 year in achieving freedom of AF/AT and a lower incidence of severe adverse events. In persistent AF, CPVI þ HFSA
offered no incremental value. (Radiofrequency Ablation of Drivers of Atrial Fibrillation [RADAR-AF]; NCT00674401)
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ABBR EV I A T I ON S
AND ACRONYMS
AAD = antiarrhythmic drug
AF = atrial ﬁbrillation
AT = atrial tachyarrhythmia
CPVI = circumferential
pulmonary vein isolation
DF = dominant frequency
HF = high frequency
HFS = high-frequency sources
HFSA = high-frequency
source ablation
LA = left atrium
PV = pulmonary vein
RF = radiofrequency
SAE = serious adverse eve
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2456C urrently-available antiarrhythmicdrugs (AADs) used to treat atrialﬁbrillation (AF) have limited efﬁ-
cacy and are frequently associated with
adverse long-term effects (1). The demon-
stration that AF triggers are most commonly
located in the pulmonary veins (PVs) led to
development of radiofrequency (RF)-based
ablative strategies aimed at creating circum-
ferential lesions around the PV ostia (1,2).
Empiric circumferential pulmonary vein
isolation (CPVI) is effective in w70% to 80%
of patients with paroxysmal AF and is the
therapy of choice for drug-refractory AF (1).
However, the procedure includes risks, and
results remain suboptimal due to PV recon-
nection and non-PV sources that maintainAF (1). Moreover, the CPVI success rate in the more
prevalent persistent AF is signiﬁcantly lower than
with paroxysmal AF, and substrate-based ablation
strategies have been proposed (1,3).
nt(s)SEE PAGE 2468Advanced signal analysis methods have demon-
strated that AF is maintained by high-frequency
sources (HFS), often located at the PV-left atrial
(LA) junction and less frequently at other sites in
both atria (4–8). Therefore, several studies have
suggested that instead of empirically targeting the
PVs, AF may be eliminated by directly ablating
AF-driving sources or “rotors” that exhibit high-
frequency, periodic activity (4–8). However, the
clinical outcomes of this mechanistically-based
strategy remain unknown.
RADAR-AF (Radiofrequency Ablation of Drivers of
Atrial Fibrillation) was a multicenter, single-blinded,
randomized clinical trial designed to compare the
efﬁcacy and safety of the standard ablation strategy
(CPVI) with a strategy of localized high-frequency
source ablation (HFSA) alone in paroxysmal AF
or combined with CPVI in persistent AF (9). We
hypothesized that: 1) in paroxysmal AF patients, the
efﬁcacy of selective HFSA would be similar to
empirical CPVI but with fewer complications; and
2) in persistent AF patients, a combination of CPVI
plus HFSA would increase efﬁcacy without increasing
complications.
METHODS
An extended version of the Methods section is
provided in the Online Appendix; a description of the
ablation strategies utilized is detailed in the following
text. The study protocol was approved by the ethicscommittee of the participating centers. All patients
provided written informed consent.
STUDY POPULATION. All patients from the outpa-
tient clinics with indication for AF ablation were
screened for eligibility. Inclusion criteria included
symptomatic paroxysmal AF, refractory/intolerant
to at least 1 AAD documented within 12 months
of randomization, anticoagulation >4 weeks prior
to inclusion, or a transesophageal echocardiogram
excluding intracardiac thrombus. Persistent AF was
deﬁned as continuous AF sustained beyond 7 days,
with patients anticoagulated for >4 weeks prior to
ablation and willing to give informed consent.
Patients were excluded if they had prior AF ablation;
inadequate anticoagulation levels; LA thrombus,
tumors, or cardiac abnormalities precluding the pro-
cedure; contraindications to systemic anticoagula-
tion; AF secondary to reversible causes; left atrial size
>55 mm; pregnancy; thyroid disease; other investi-
gational study involvement; and implanted device.
STUDY DESIGN. Randomization was performed
according to AF type using a web-based system and
was balanced at each site. Paroxysmal AF patients
were randomly assigned 1:1 to CPVI or HFSA. Persis-
tent AF patients were randomly assigned 1:1 to CPVI
or a combined ablation approach (CPVI þ HFSA).
Because of the nature of the intervention, physicians
performing the ablation procedure were not blinded
to treatment group assignment.
FOLLOW-UP. Patients were followed by physicians
blinded to the assigned treatment arm at 3, 6, and 12
months from the ﬁrst ablation procedure, and 12-lead
electrocardiogram, 48-h Holter recordings, and qual-
ity of life (QOL) questionnaires were obtained at each
follow-up visit. Holter analysis was blinded with
respect to randomization and treatment. All adverse
events were reviewed and adjudicated by an inde-
pendent data safety monitoring committee.
ABLATION PROCEDURE AND STRATEGIES. Electro-
physiological study common to all patients. AADs
were stopped >5 half-lives prior to the procedure,
except for amiodarone. In patients arriving in sinus
rhythm (SR), AF was induced following a standard-
ized protocol (8). If AF was not sustained for >5 min,
the patient was excluded from study. Once in AF, the
patient was randomized. Three-dimensional geome-
try of the atria was reconstructed using the Ensite
NavX System version 8.0 (St. Jude Medical, Minne-
apolis, Minnesota) (8). RF energy was delivered using
a 3.5-mm irrigated-tip ablation catheter (Therapy
Cool Path, St. Jude Medical, St. Paul, Minnesota).
CPVI st rategy . In patients assigned to CPVI, the PVs
were isolated using circumferential lesions around
FIGURE 1 Study Ablation Strategies
(A) Circumferential pulmonary vein isolation (CPVI) as seen from the left atrial (LA) pos-
terior view. Red dots indicate ablation lesions. (B) High-frequency source ablation (HFSA)
as seen in this LA dominant frequency (DF) map, posterior view, showing an HFS located at
the antrum of the right inferior pulmonary vein. Yellow dots indicate ablation lesions.
(C) CPVI þ HFSA is illustrated in LA and right atrial DF maps, anterior (right) and posterior
(left) view, showing CPVI and HFSA lesions (white dots).
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2457the PV antrum with conﬁrmation of entrance block
using a multipolar circular catheter (Figure 1A). An
additional roof line was allowed, but conduction
block across the line was not formally required.
Organized atrial tachyarrhythmias (ATs) or ﬂutter
occurring after CPVI could be mapped and ablated at
the discretion of the investigator. If the patient was
in AF at the procedure’s end, he/she could be
cardioverted, and remapping was performed to con-
ﬁrm PV isolation. Termination and/or noninducibility
of AF were not procedural endpoints.
HFSA strategy . A high-density dominant frequency
(DF) LA map was created by sequentially moving the
ablation and/or circular mapping catheter throughout
the entire left atrium. Sites with high-frequency (HF)
atrial electrograms were identiﬁed by an automated
algorithm designed to calculate the DF and depict local
atrial activation frequency on the 3-dimensional LA
shell (Figure 1B) (8). HFS were targeted until ablation
endpoints were reached: 1) elimination of all HFS or
conversion to SR; and 2) noninducibility of AF post-
ablation. If AF did not terminate after LA HFSA,
DFmaps from the right atrium (RA) and coronary sinus
(CS) were obtained and HFS were targeted at the op-
erator’s discretion. A maximum of 3 to 4 HFS per
chamber were targeted for ablation (4 sites in LA and 3
sites in RA and CS). Ablation of HF sites located at a PV
antrum was performed by creating a circumferential
set of lesions around the ostiumof the responsible vein
until PV isolation was obtained (Figure 1B) (7,9). HF
sites located elsewhere in the atria were targeted for
ablation until local potentials were completely abated
through creation of a coin-like circumferential set of
lesions. Organized ATs occurring after elimination of
HF sites could be mapped and ablated at the in-
vestigator’s discretion. If AF persisted despite elimi-
nation of all HF sites from the LA, RA, and CS, the AF
could be cardioverted and the procedure terminated.
Combined strategy : CPVI D HFSA. A high-density
DF LA map was obtained and then CPVI was per-
formed. If the patient remained in AF, HFS were
targeted for ablation, according to the previously
described protocol, until ablation endpoints were
reached: 1) elimination of HFS; and 2) PV isolation
(Figure 1C). If AF did not terminate after LA HFSA, RA
and CS DF maps were obtained and HFS was targeted
(at operator discretion). If AF persisted despite elim-
ination of all HFS from the LA, RA, and CS, AF could
be cardioverted and the procedure terminated.
Redo procedures . A 2-month blanking period was
observed, after which AADs were discontinued. Redo
procedures due to recurrent AF were not allowed
within the ﬁrst 6 months; they were performed 6 to
7.5 months post-ablation using the same strategyassigned in the ﬁrst procedure, except for the
HFSA-only arm, where the investigator could perform
either CPVI or HFSA.
STUDY OUTCOMES. The primary endpoint was
freedom from AF at 6 months post-ﬁrst ablation
procedure off of AADs. Secondary endpoints included
freedom from AF/AT at 6 and 12 months off/on AADs;
need for redo procedures; incidence of periprocedural
complications and overall adverse events; ﬂuoros-
copy time and procedure duration; and QOL at base-
line and at 3, 6, and 12 months assessed using the
speciﬁc AF-QOL questionnaire (10). Recurrent AF/AT
was deﬁned as AF/AT of at least 30 s duration docu-
mented by electrocardiogram or device recording
system >2 months following catheter ablation (1).
SAFETY OUTCOMES. Adverse events were classiﬁed
according to their seriousness and whether they were
procedure related (Online Appendix) (1).
STATISTICAL METHODS. The primary hypothesis
in paroxysmal AF was that HFSA would be noninferior
and associated with lower risk than CPVI. If
noninferiority was achieved in the primary analysis,
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ority. Secondary efﬁcacy and safety endpoints
also were tested for superiority. All analyses
were intention-to-treat. Statistical signiﬁcance was
considered 1-sided for paroxysmal and 2-sided for
persistent AF and was declared if the p value
was <0.05. Comparison of time to event was per-
formed using Kaplan-Meier analysis and the log-rank
test. Continuous baseline variables were compared
using the Student t test or Mann-Whitney test ac-
cording to the variables statistical distribution. Cate-
gorical variables were compared using Fisher exact
test. Repeated measures analysis of variance was used
to examine the effect of treatment strategy by time on
QOL for each group. All statistical analyses were per-
formed using SPSS version 17.0 (IBM, Armonk, New
York) and Comprehensive Meta-Analysis version 2.2
(Biostat Inc., Englewood, New Jersey).TABLE 1 Baseline Characteristics of Patients
Paroxysmal AF (n ¼ 113)
CPVI
(n ¼ 58)
HFSA
(n ¼ 55)
Male 49 (84) 40 (73)
Age, yrs 53  10 54  12
BMI, kg/m2 27.5  4.2 28  3.1
Medical history
Hypertension 17 (29) 24 (44)
Dyslipidemia 16 (27) 22 (40)
Diabetes 2 (3) 3 (5)
Alcohol 2 (3) 3 (5)
Tobacco 26 (45) 21 (38)
Previous stroke/TIA 2 (3) 0
Structural heart disease 7 (12) 12 (22)
Valvular disease 4 (7) 4 (7)
AF diagnosis, yrs 4.13 (1.45-8.77) 3.66 (1.1-9.4)
LVEF, % 60 (60–65) 60 (60–65)
LA diameter, mm 40  5 40  6
NYHA functional class
I 52 (90) 51 (93)
II 6 (10) 4 (7)
III
CHADS2 score*
0 36 (62) 29 (53)
1 19 (33) 22 (40)
$2 3 (5) 4 (7)
Prior AAD use
1 33 (57) 40 (73)
2 21 (36) 10 (18)
3 4 (7) 4 (7)
4 0 (0) 1 (1.8)
Values are n (%), mean  SD, or median (interquartile range). *CHADS2 score awards
2 points for stroke.
AAD ¼ antiarrhythmic drug; AF ¼ atrial ﬁbrillation; BMI ¼ body mass index; CHADS2
transient ischemic attack; CPVI ¼ circumferential pulmonary vein isolation; HFSA ¼ high-
NYHA ¼ New York Heart Association; TIA ¼ transient ischemic attack.RESULTS
We enrolled 232 patients (115 [49%] paroxysmal AF
and 117 [51%] persistent AF) between May 2009 and
May 2012, with last follow-up in May 2013. The
2 groups were well-matched with respect to baseline
clinical characteristics (Table 1). Mean age was 54 
10 years, and 20% of the patients were women. One
patient was excluded due to protocol violation, 1 was
lost to follow-up, and 3 withdrew consent after
6-month follow-up (Figure 2).
ABLATION PROCEDURE. In paroxysmal AF patients
assigned to HFSA, after 31  16 min, DF mapping
identiﬁed a median of 3 HFS (interquartile range
[IQR]: 2 to 4 HFS) per patient (Table 2, Figure 3).
Overall, a median of 2.87 HFS (IQR: 2 to 3 HFS) were
ablated; 18 sites were not ablated due to anatomical
restrictions or safety concerns. In CPVI patients,Persistent AF (n ¼ 117)
p Value
CPVI
(n ¼ 58)
CPVI þ HFSA
(n ¼ 59) p Value
0.168 47 (81) 48 (81) 0.965
0.693 54  10 55  9 0.568
0.439 28.7  3.7 29.1  3.4 0.50
0.123 20 (34) 29 (49) 0.108
0.171 20 (34) 15 (25) 0.285
0.674 5 (9) 8 (14) 0.395
0.674 2 (3) 4 (7) 0.414
0.567 22 (38) 26 (44) 0.50
NA 4 (7) 4 (7) 0.98
0.211 22 (38) 17 (29) 0.296
1.00 10 (17) 4 (7) 0.081
0.745 1.32 (0.50-4.87) 1.5 (0.58-3.75) 0.719
0.801 60 (54.8–60.0) 60 (55–62) 0.657
0.791 45  7 45  6 0.922
0.743 0.113
50 (86) 42 (71)
8 (14) 16 (27)
0 1 (2)
0.595 0.149
33 (57) 23 (39)
18 (31) 25 (42)
7 (12) 11 (19)
0.139 0.379
32 (55) 34 (58)
22 (38) 24 (41)
4 (7) 1 (2)
1 point for congestive heart failure, hypertension, age $75 years, and diabetes, and
¼ congestive heart failure, hypertension, age $75 years, diabetes mellitus, stroke/
frequency source ablation; LA ¼ left atrium; LVEF ¼ left ventricular ejection fraction;
FIGURE 2 Patient Inclusion Flow Chart
58 Patients
 analyzed
at 1 year
57 Patients
 analyzed
at 1 year
58 Patients
analyzed
at 1 year
54 Patients 
analyzed
at 1 year
1 Patient excluded
protocol violation
1 Patient lost
to follow up
1 Patient 
withdrawn
consent
1 Patient 
withdrawn
consent
1 Patient 
withdrawn
consent
56 Patients
HFSA strategy
59 Patients
CPVI strategy
232 Patients
randomized
823 Patients
assessed for
eligibility
Paroxysmal AF
115 patients
Persistent AF
117 patients
58 Patients
CPVI strategy
59 Patients
HFSA+CPVI
combined strategy
591 Excluded:
477 Did not meet inclusion criteria:
182 Previous AF ablation
116 Included in other protocols
or ablation technologies
33 Thyroid dysfunction
17 Non-inducible AF >5 min
129 Other
114 Refused participation
55 Patients
analyzed at 6
months
58 Patients
analyzed at 6
months
59 Patients
analyzed at 6
months
58 Patients
analyzed at 6
months
Patient distribution according to eligibility, atrial ﬁbrillation (AF) type, ablation strategy assignment, and follow-up duration. Abbreviations as
in Figure 1.
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24593.79  0.5 veins were isolated compared with
2.22  1.1 in the HFSA group (p < 0.001). Delivered
RF time was signiﬁcantly shorter in patients under-
going HFSA versus CPVI (p < 0.01). A signiﬁcantly
higher percentage of patients undergoing HFSA
converted to SR during ablation (45% vs. 28%;
p < 0.05).
In persistent AF patients assigned to CPVI þ HFSA,
after 28  17 min, DF mapping identiﬁed a median
of 3 HFS (IQR: 2 to 5 HFS) per patient (Figure 3),
3.88  0.45 veins were isolated, and a median of 3 HFS
(IQR: 2 to 4.25 HFS) were ablated; 26 HFS were not
ablated. In persistent AF patients assigned to CPVI,
3.93  0.45 veins were isolated. Compared with the
CPVI group, the CPVI þ HFSA group had signiﬁcantly
longer procedure duration and a trend toward longerRF duration (Table 2) (see Online Appendix for further
details).
EFFICACY OUTCOMES. In paroxysmal AF, freedom
from AF without AADs at 6 months (primary
endpoint) was seen in 83% of CPVI versus 73% of
HFSA patients (risk difference [RD]: 0.1; lower
limit 1-sided 95% conﬁdence interval [CI]: 0.228;
p ¼ 0.228 for noninferiority; p ¼ 0.901 for superiority)
(Figure 4). Freedom from AF/AT at 6 months also was
similar (69% of CPVI vs. 65% of HFSA patients;
RD: 0.035; lower limit 1-sided 95% CI: 0.18;
p ¼ 0.08 for noninferiority; p ¼ 0.654 for superiority).
After a single procedure, time to ﬁrst AF recurrence
and time to ﬁrst AF/AT recurrence were not signiﬁ-
cantly different between groups (Figure 5). At 1 year,
freedom from AF was seen in 79% of CPVI and 81% of
TABLE 2 Procedural Characteristics
Paroxysmal AF Persistent AF
CPVI
(n ¼ 58)
HFSA
(n ¼ 55) p Value
CPVI
(n ¼ 58)
CPVI þ HFSA
(n ¼ 59) p Value
Induced AF 46 (81) 49 (89) 0.26 11 (19) 11 (19) 0.61
Mean AF cycle length, ms 172  35 176  33 0.55 171  33 169  33 0.79
DF mapping time, min NA 31  16 NA NA 28  17 NA
RF time, min 36 (24.7–47.1) 29 (20–39) 0.01 37 (29.7–50.0) 43 (31–53) 0.10
Fluoroscopy time, min 60 (45.8–79.3) 59 (40–81) 0.66 66 (47–78.3) 67 (50–83) 0.43
Total procedure time, min 215  66 228  65 0.31 202  58 239  61 0.001
HFS NA 3 (2–4) NA NA 3 (2–5) NA
Ablated HFS NA 2.87 (2–3) NA NA 3 (2.00–4.25) NA
Total number nonablated HFS NA 18 NA NA 26 NA
Isolated pulmonary veins 3.79  0.50 2.22  1.10 <0.001 3.93  0.45 3.88  0.45 0.56
Patients with additional ablation lines 3 0 NA 11 22 0.03
Patients converting to SR during ablation 16 (28) 25 (45) <0.05 3 (5) 7 (12) 0.19
Patients converting to AT during ablation 6 (10) 7 (13) 0.69 12 (21) 20 (34) 0.11
Patients with redo procedures 17 (29) 13 (24) 0.5 13 (22) 16 (27) 0.56
Ablated HFS during redo procedure NA 3 (1.75–3.00) NA NA 3 (1.5–5.0) NA
Isolated pulmonary veins during redo procedure 3.59  1.00 2.46  0.96 0.004 2.92  1.40 3.31  0.79 0.36
Values are n (%), mean  SD, or median (interquartile range).
AT ¼ atrial tachyarrhythmias; DF ¼ dominant frequency; RF ¼ radiofrequency; SR ¼ sinus rhythm; other abbreviations as in Table 1.
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2460HFSA patients (RD: 0.022; lower limit 1-sided 95%
CI: 0.102; p ¼ 0.008 for noninferiority; p ¼ 0.385 for
superiority), and freedom from AF/AT was seen in
72% of CPVI vs. 76% of HFSA patients (RD: 0.054;
lower limit 1-sided 95% CI: 0.08; p ¼ 0.004 forFIGURE 3 Schematic Diagram of HFS Distribution in the Atria
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RSPV ¼ right superior pulmonary vein; RIPV ¼ right inferior pulmonarynoninferiority; p ¼ 0.255 for superiority). After redo
procedures, time to ﬁrst AF or AF/AT recurrence was
not signiﬁcantly different between groups (Figure 5).
In persistent AF, freedom from AF without AADs
at 6 months was seen in 60% of CPVI versus 61% ofMV TV
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in paroxysmal AF, whereas a more widespread distribution is found in
trium. CS ¼ coronary sinus; IVC ¼ inferior vena cava; LAA ¼ left atrial
lmonary vein; MV ¼ mitral valve; RAA ¼ right atrial appendage;
vein; SVC ¼ superior vena cava; TV ¼ tricuspid valve.
FIGURE 4 Comparisons of Efﬁcacy and Safety Endpoints
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Forest plots compare CPVI versus HFSA only in paroxysmal AF and CPVI versus CPVI þ HFSA in persistent AF. AE ¼ adverse events; AT ¼ atrial tachycardia; other
abbreviations as in Figures 1 and 2.
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2461CPVI þ HFSA patients (RD: 0.007; 95% CI: 0.17 to
0.184; p ¼ 0.941). Similarly, freedom from AF/AT at
6 months was seen in 60% of CPVI versus 56% of
CPVI þ HFSA patients (RD: 0.044; 95% CI: 0.223
to 0.134; p ¼ 0.628). After a single procedure, time
to ﬁrst AF recurrence and ﬁrst AF/AT recurrence
were not signiﬁcantly different between groups
(Figure 6). At 1 year, freedom from AF was seen
in 65% of CPVI and 69% of CPVI þ HFSA patients
(RD: 0.041; 95% CI: 0.131 to 0.212; p ¼ 0.644),
whereas freedom from AF/AT was seen in 63%
CPVI versus 67% CPVI þ HFSA patients (RD: 0.041;
95% CI: 0.133 to 0.215; p ¼ 0.646). After redo
procedures, time to ﬁrst AF or ﬁrst AF/AT recur-
rence did not differ signiﬁcantly between groups
(Figure 6).
SAFETY OUTCOMES. In paroxysmal AF patients,
procedure-related adverse events occurred in 8 (14%)
patients in the CPVI versus 3 (5%) patients in the
HFSA group (RD: 0.083; upper limit 1-sided 95% CI:
0.007; p ¼ 0.068 for superiority) (Table 3, Figure 4),whereas overall serious adverse events (SAE)
occurred in 5 (9%) patients in the HFSA and 14 (24%)
in the CPVI group (RD: -0.15; upper limit 1-sided
95% CI: 0.038; p ¼ 0.017 for superiority). In persis-
tent AF patients, procedure-related adverse events
occurred in 2 (3%) patients in the CPVI and 6 (10%)
in the CPVI þ HFSA group (RD: 0.067; 95% CI: 0.023
to 0.158; p ¼ 0.145), whereas overall SAEs occurred
in 6 (10%) patients in the CPVI versus 14 (24%)
in the CPVI þ HFSA group (RD: 0.134; 95% CI: 0 to
0.268; p ¼ 0.05).
REDO PROCEDURES. In paroxysmal AF patients,
there was no signiﬁcant difference in the proportions
of patients undergoing redo procedures (Table 2). In
patients assigned to CPVI (n ¼ 17), all but 1 patient had
3.59  1.0 reconnected veins that were re-isolated,
and 3 patients underwent additional linear ablation
in the LA. In patients assigned to HFSA (n ¼ 13), CPVI
was performed in 2 due to operator preference and in 1
due to the absence of HFS in the atria; in the
remaining, a median of 3 HFS (IQR: 1.75 to 3 HFS)
FIGURE 5 Survival Curves for Paroxysmal AF Patients
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Kaplan-Meier curves of time to ﬁrst AF and time to ﬁrst AF/AT recurrence after a single procedure (left) and after redo procedures (right) in paroxysmal AF patients
undergoing CPVI versus HFSA. Abbreviations as in Figures 1, 2, and 4.
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2462were identiﬁed and ablated with 2.46  0.96 veins
concomitantly isolated. All PVs harboring HFS ablated
at the redo procedure had been previously isolated
during the index procedure, whereas the rest of the
veins were spared.
In persistent AF patients, there also was no sig-
niﬁcant difference in the proportion of patientsundergoing redo procedures (Table 2). Of the patients
assigned to CPVI (n ¼ 13), 11 had 2.92  1.4 recon-
nected veins that were re-isolated, 7 underwent
additional linear ablation, and 1 underwent addi-
tional HFSA. In patients assigned to CPVI þ HFSA
(n ¼ 16), 3.31  0.79 veins were reconnected and
re-isolated. Five patients did not undergo DF
FIGURE 6 Survival Curves for Persistent AF Patients
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Kaplan-Meier curves of time to ﬁrst AF and time to ﬁrst AF/AT recurrence after a single procedure (left) and after redo procedures (right) in persistent AF patients
undergoing CPVI versus CPVI þ HFSA. Abbreviations as in Figures 1, 2, and 4.
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2463mapping due to operator preference (n ¼ 3), technical
failure (n ¼ 1), and SR conversion during CPVI and
noninducibility (n ¼ 1); in the remaining patients, a
median of 3 (IQR: 1.5 to 5) HFS were identiﬁed and
ablated.
QOL OUTCOMES. Baseline QOL measures were
similar between treatment groups in both AF types.There was a progressive improvement in physical,
mental, and sexual QOL scores at 6 and 12 months
after ablation in both treatment groups and AF types
(Table 4). However, QOL comparisons between
treatment groups in both AF types at 6 and 12 months
post-ablation were not signiﬁcantly different (Online
Appendix).
TABLE 3 Serious Adverse Events
Paroxysmal AF Persistent AF
CPVI HFSA CPVI CPVI þ HFSA
Procedural adverse events
Pericarditis/chest pain 1 1
Tamponade 2 1 2
Pericardial effusion conservatively treated 2
Vascular complications 1 1 1 1
Pleural effusion 1
Pneumonia <1 month after ablation 1 2
PV stenosis 1
Urinary tract infection 1
Adverse events >1 month after the procedure
Hypotension/HF after cardioversion for AF 1 1 1
AF/AT/ﬂutter requiring hospitalization/ablation 5 1 1 5
Syncope 1
Thyroid dysfunction 1
Bleeding after surgery 1 1
Chest pain 1 1
Stroke after switching acenocumarol for dabigatran 1
Traumatism with hospital admission* 1 1 1
Pharmacologic AV block† 1
Events reported as serious adverse events during the study follow-up; some patients had more than 1 serious
adverse event. *Traumatisms due to accidents or causal falls not related to cardiac events. †Pharmacologic AV
block 2 months after the procedure due to beta-blocker treatment that resolved after discontinuation.
AV ¼ atrioventricular; HF ¼ heart failure; other abbreviations as in Tables 1 and 2.
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This prospective randomized study demonstrates
that in paroxysmal AF patients, an ablation strategy
targeting HFS until AF termination did not reach
noninferiority compared with CPVI after a single
procedure to achieve freedom of AF at 6 months.
However, after redo ablation procedures, HFSA was
noninferior to empiric CPVI at 12 months to achieve
freedom from AF and AT. Importantly, patients un-
dergoing HFSA had a signiﬁcantly lower incidence of
SAEs. In contrast, in persistent AF patients, adding
HFSA to CPVI offered no incremental value and
showed a trend toward more complications compared
with CPVI.
THE ROLE OF HFS IN AF MAINTENANCE. Techniques
aimed at empirically isolating the PVs yield success
rates that barely surpass the 60% to 70% midterm
efﬁcacy rate reported with multiple procedures and
AADs, and yet they increase risks and cost (1,3).
Consequently, interest has grown in mechanistically-
based ablation strategies that might be more effective
and safe. Experimental studies have demonstrated
that AF is maintained by HFS (rotors or drivers)
anchored at the posterior LA wall and the junction
with the PVs (11). Studies by Haïssaguerre et al. (2)demonstrated that rapidly-ﬁring ectopic foci in the
PVs were capable of initiating and even maintaining
AF and could be eliminated with RF ablation. Such
ﬁndings paved the way for the currently used CPVI
ablation technique, aimed at electrically isolating the
PVs from the atrium (1). However, in persistent AF,
CPVI is less effective, and more extensive ablative
techniques have been proposed (1,3,12–15), which in-
crease not only the procedure time and ﬂuoroscopic
exposure, but also the risk of complications (15). For
all of these reasons, a search for alternative mapping
and ablation strategies is urgently needed.
BENCH-TO-BEDSIDE TRANSLATIONAL RESEARCH. In a
series of forward translational studies, we have used
spectral analysis techniques developed and validated
in the animal laboratory to identify and ablate HFS in
AF patients (4,6–9,11). Those studies showed that
real-time spectral mapping of AF was safe and
enabled identiﬁcation and effective elimination of
HFS, leading to favorable long-term SR maintenance
rates. Based on such ﬁndings, we hypothesized that
in paroxysmal AF, more selective ablation of sites
responsible for AF maintenance would be as effective
as CPVI while decreasing complication risks (Central
Illustration) (9). Although we failed to demonstrate
noninferiority for the primary endpoint at 6 months,
this result reﬂects only single procedure efﬁcacy.
Nevertheless, there was a trend toward statistical
signiﬁcance in the secondary endpoint of freedom
from AF/AT at 6 months (p ¼ 0.08 for noninferiority).
At 1 year, HFSA provided similar efﬁcacy rates in
terms of freedom from AF and AF/AT compared with
CPVI, despite shorter delivered RF time and fewer
isolated veins. Noninferiority could only be reached
after redo procedures, with reconnection of previ-
ously ablated PVs harboring HFS the dominant
recurrence mechanism in this group. Moreover, long-
term complications were signiﬁcantly reduced in the
HFSA-only group.
The results concur with other studies using elec-
trophysiological instead of purely anatomic end-
points. In a randomized single-center study, Dixit et al.
(16) demonstrated that isolation of arrhythmogenic
veins was as efﬁcacious as empiric isolation of all veins
in achieving long-term AF control, with all serious
procedural events occurring in the empiric isolation
arm. Using a different approach, Oral et al. (17) showed
that rendering AF noninducible by additional LA
ablation after CPVI was associated with better clinical
efﬁcacy, but it increased the incidence of LA ﬂutter.
Narayan et al. (18) used a novel computationally-based
mapping approach to reveal AF rotors in the left or
right atrium, then selectively ablated them with
TABLE 4 Quality of Life Assessment With Change From Baseline to 6 and 12 Months
AF-QOL Questionnaire
Mean Change
Baseline vs. 6 Months
Mean Difference
Between Groups p Value*
Mean Change
Baseline vs. 12 Months
Mean Difference
Between Groups p Value*
Paroxysmal AF
CPVI HFSA CPVI HFSA
Physical scores 20.6  4.3 17.4  3.8 3.2  5.7 0.578 26.4  4.9 22.7  4.3 3.71  5.5 0.569
Mental scores 21.1  4.7 15.1  3.5 5.9  5.7 0.3 30.6  5.1 21  3.9 8.6  6.4 0.137
Sexual scores 8.7  4.7 11.6  5.3 2.9  7.2 0.687 23.7  5.4 15.5  5.6 8.2  8.1 0.315
Persistent AF
CPVI CPVI þ HFSA CPVI CPVI þ HFSA
Physical scores 20.5  4.5 15.1  4.2 5.4  6.2 0.387 31.2  3.4 25.2  3.9 6  5.2 0.251
Mental scores 14.9  3.9 9.1  3 6  5 0.237 24  3.5 16  4 8  5.3 0.135
Sexual scores 4  5.2 10.1  5.8 6.1  7.8 0.436 17  4.8 12.1  5.5 4.9  7. 3 0.506
Values are mean  SE. *Student t test for paired data.
CENTRAL ILLUSTRATION Ablation Strategies Compared in Patients
With Paroxysmal Atrial Fibrillation
Empiric circumferential pulmonary vein isolation was compared with high-frequency
source ablation. The dominant frequency map (left) enabled detection of the highest
frequency (purple) source (rotor) located at the left inferior pulmonary vein (1) with
ﬁbrillatory conduction to the right atrium (2) that activated at the lowest rate (red to
white), as shown in boxes 1 and 2, where local bipolar recordings and the corresponding
power spectrum are depicted.
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2465favorable long-term results. More recently, the
PRECISE-AF trial demonstrated that AF source abla-
tion alone can eliminate paroxysmal AF without the
need to ablate the PVs (19). However, these single-
center experiences have not been reproduced in large
(n>100) randomizedmulticenter trials. Ours is theﬁrst
mechanistically-based randomized AF ablation trial
that derives from translation of basic science knowl-
edge into AF therapy (20).
In persistent AF, we found a more evenly-spaced
distribution of HFS (Figures 1 and 3) (4,7), with efﬁ-
cacy of CPVI þ HFSA similar to CPVI but with a trend
toward higher complication rates. Several factors
might account for these disappointing results: 1) a
relevant number of HFS were spared from ablation
due to safety concerns, precluding elimination of
critical DF sites maintaining AF (Online Appendix);
2) atrial ﬁbrosis increases AF complexity in persistent
patients, precluding accurate DF measurement; and/
or 3) the mechanisms underlying the maintenance of
AF in these patients might be undetectable using DF.
Substrate modiﬁcation strategies have been com-
bined with CPVI to try to enhance procedural efﬁcacy
in patients with persistent AF (12–15). Like our trial,
other randomized studies found that additional sub-
strate modiﬁcation beyond PVI did not improve
efﬁcacy in patients with persistent AF (13,14). In
contrast, efﬁcacy increased with CPVI followed by
automatic complex fractionated electrogram ablation
(12) and rotor/focal sources ablation followed by CPVI
(18). These conﬂicting data suggest that additional
extensive substrate modiﬁcation beyond PVI, specif-
ically DF ablation, does not consistently improve
procedure efﬁcacy. Hence, further research is needed
to enable detection and elimination of extrapulmo-
nary vein sources of AF maintenance in this patient
population.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE 1: The
PVs are the most common location of triggers for AF,
and CPVI has become the therapy of choice for drug-
refractory AF. However, procedural risks and subop-
timal results due to non-PV sources that maintain AF
are important limitations. Whether the ablation of
non-PV triggers, complex fractionated electrograms,
rotors, or focal sources (localized HFSA), alone or in
combination with CPVI is associated with greater
procedural success or long-term complications
compared with CPVI alone has not been established.
COMPETENCY IN MEDICAL KNOWLEDGE 2:
In patients with paroxysmal AF, HFSA proved to be
noninferior to CPVI in achieving freedom from atrial
tachyarrhythmias at 1 year after the procedures and
was associated with a lower incidence of severe
adverse events. In persistent AF, however, procedures
combining CPVI with HFSA did not provide incre-
mental value and were associated with a trend to
increase complications risk.
TRANSLATIONAL OUTLOOK: Further advances in
arrhythmia mapping and signal analysis technologies
that increase the accuracy and completeness of abla-
tion of sources driving AF could inﬂuence the relative
efﬁcacy and safety of the CPVI and HFSA strategies.
Atienza et al. J A C C V O L . 6 4 , N O . 2 3 , 2 0 1 4
Catheter Ablation of AF Drivers D E C E M B E R 1 6 , 2 0 1 4 : 2 4 5 5 – 6 7
2466Our periprocedural complication rate of 8% is
comparable to previous studies, large administrative
databases, and registries (12,21). Our long-term SAE
rate (16.9%) was slightly higher than recent random-
ized studies in paroxysmal (14.2%) and persistent AF
(15.9%) patients (22,23), but lower than the European
Atrial Fibrillation Ablation Pilot registry that also
included post-ablation AT/ﬂutter as a procedural
complication (26.5%) (24). Our results suggest that in
paroxysmal AF, a more limited mechanistically-based
ablation strategy is safer than empirically isolating
the PVs. In contrast, in persistent AF, extensive atrial
ablation techniques including atrial lines, fraction-
ated electrogram ablation, or HFSA added to CPVI, are
associated with an increased rate of complications
(15,16). Therefore, the present study calls into ques-
tion the generalized use of ablation strategies aimed
at creating extensive lesions in the atria of patients
with persistent AF.
STUDY LIMITATIONS. DF mapping and detailed re-
view of measured DFs was required to eliminate
spurious measurements, which increased procedure
time. Also, sequential data point acquisition may
raise concerns regarding DF spatiotemporal stability.
Due to safety concerns, several HFS were spared from
ablation, and prior evidence suggests a better
outcome would have been expected after ablation of
all HFS (7). Finally, more extensive electrocardiogram
monitoring may have detected additional episodes of
AF, but this may affect both treatment arms.
CONCLUSIONS
In paroxysmal AF, HFSA failed to achieve non-
inferiority at 6 months after a single procedure but
was as efﬁcacious as CPVI in achieving freedom of AF/
AT at 1 year, with a lower incidence of SAEs. In
persistent AF, CPVI þ HFSA offered no incremental
value, with a trend toward increased complications.
These results may offer a novel mechanistic treat-
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